A carregar...
Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
INTRODUCTION: Breast cancer is the most common malignancy in women in the United States and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for metastatic TNBC has been limited to cytotoxic chemotherapy with modest efficacy. TNBC is associated with high levels of tumor...
Na minha lista:
| Publicado no: | Expert Rev Precis Med Drug Dev |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7080186/ https://ncbi.nlm.nih.gov/pubmed/32190733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23808993.2020.1730694 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|